Laura Brugnara1,2, Ana Isabel García1,3, Serafín Murillo1,2, Josep Ribalta4,2, Guerau Fernandez5, Susanna Marquez6, Miguel Angel Rodriguez7, Maria Vinaixa7, Núria Amigó7,8,2, Xavier Correig7,2, Susana Kalko1,9, Jaume Pomes3, Anna Novials10,11. 1. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clínic de Barcelona, Carrer del Rosselló, 149, 08036, Barcelona, Spain. 2. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. 3. Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain. 4. Departament de Medicina i Cirugia, Universitat Rovira i Virgili/Unitat de Recerca en Lípids i Arteriosclerosi, IISRV, Reus, Spain. 5. Bioinformatics Unit, Genetics and Molecular Medicine Service, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain. 6. Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. 7. Metabolomics Platform, Universitat Rovira i Virgili, IISRV, Reus, Spain. 8. Biosfer Teslab, Reus, Spain. 9. Bioinformatics Core Facility (IDIBAPS), Barcelona, Spain. 10. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clínic de Barcelona, Carrer del Rosselló, 149, 08036, Barcelona, Spain. anovials@clinic.cat. 11. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. anovials@clinic.cat.
Abstract
PURPOSE: Muscle is an essential organ for glucose metabolism and can be influenced by metabolic disorders and physical activity. Elevated muscle carnosine levels have been associated with insulin resistance and cardiometabolic risk factors. Little is known about muscle carnosine in type 1 diabetes (T1D) and how it is influenced by physical activity. The aim of this study was to characterize muscle carnosine in vivo by proton magnetic resonance spectroscopy (1H MRS) and evaluate the relationship with physical activity, clinical characteristics and lipoprotein subfractions. METHODS: 16 men with T1D (10 athletes/6 sedentary) and 14 controls without diabetes (9/5) were included. Body composition by DXA, cardiorespiratory capacity (VO2peak) and serum lipoprotein profile by proton nuclear magnetic resonance (1H NMR) were obtained. Muscle carnosine scaled to water (carnosineW) and to creatine (carnosineCR), creatine and intramyocellular lipids (IMCL) were quantified in vivo using 1H MRS in a 3T MR scanner in soleus muscle. RESULTS: Subjects with T1D presented higher carnosine CR levels compared to controls. T1D patients with a lower VO2peak presented higher carnosineCR levels compared to sedentary controls, but both T1D and control groups presented similar levels of carnosineCR at high VO2peak levels. CarnosineW followed the same trend. Integrated correlation networks in T1D demonstrated that carnosineW and carnosineCR were associated with cardiometabolic risk factors including total and abdominal fat, pro-atherogenic lipoproteins (very low-density lipoprotein subfractions), low VO2peak, and IMCL. CONCLUSIONS: Elevated muscle carnosine levels in persons with T1D and their effect on atherogenic lipoproteins can be modulated by physical activity.
PURPOSE: Muscle is an essential organ for glucose metabolism and can be influenced by metabolic disorders and physical activity. Elevated muscle carnosine levels have been associated with insulin resistance and cardiometabolic risk factors. Little is known about muscle carnosine in type 1 diabetes (T1D) and how it is influenced by physical activity. The aim of this study was to characterize muscle carnosine in vivo by proton magnetic resonance spectroscopy (1H MRS) and evaluate the relationship with physical activity, clinical characteristics and lipoprotein subfractions. METHODS: 16 men with T1D (10 athletes/6 sedentary) and 14 controls without diabetes (9/5) were included. Body composition by DXA, cardiorespiratory capacity (VO2peak) and serum lipoprotein profile by proton nuclear magnetic resonance (1H NMR) were obtained. Muscle carnosine scaled to water (carnosineW) and to creatine (carnosineCR), creatine and intramyocellular lipids (IMCL) were quantified in vivo using 1H MRS in a 3T MR scanner in soleus muscle. RESULTS: Subjects with T1D presented higher carnosine CR levels compared to controls. T1D patients with a lower VO2peak presented higher carnosineCR levels compared to sedentary controls, but both T1D and control groups presented similar levels of carnosineCR at high VO2peak levels. CarnosineW followed the same trend. Integrated correlation networks in T1D demonstrated that carnosineW and carnosineCR were associated with cardiometabolic risk factors including total and abdominal fat, pro-atherogenic lipoproteins (very low-density lipoprotein subfractions), low VO2peak, and IMCL. CONCLUSIONS: Elevated muscle carnosine levels in persons with T1D and their effect on atherogenic lipoproteins can be modulated by physical activity.
Authors: Bryan C Bergman; David Howard; Irene E Schauer; David M Maahs; Janet K Snell-Bergeon; Robert H Eckel; Leigh Perreault; Marian Rewers Journal: J Clin Endocrinol Metab Date: 2012-02-22 Impact factor: 5.958
Authors: Gaia Botteri; Marta Montori; Anna Gumà; Javier Pizarro; Lídia Cedó; Joan Carles Escolà-Gil; Diana Li; Emma Barroso; Xavier Palomer; Alison B Kohan; Manuel Vázquez-Carrera Journal: Diabetologia Date: 2017-08-23 Impact factor: 10.122
Authors: Douglas E Befroy; Kitt Falk Petersen; Sylvie Dufour; Graeme F Mason; Robin A de Graaf; Douglas L Rothman; Gerald I Shulman Journal: Diabetes Date: 2007-02-07 Impact factor: 9.461
Authors: Laura Brugnara; Roger Mallol; Josep Ribalta; Maria Vinaixa; Serafín Murillo; Teresa Casserras; Montse Guardiola; Joan Carles Vallvé; Susana G Kalko; Xavier Correig; Anna Novials Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Laura Brugnara; Maria Vinaixa; Serafín Murillo; Sara Samino; Miguel Angel Rodriguez; Antoni Beltran; Carles Lerin; Gareth Davison; Xavier Correig; Anna Novials Journal: PLoS One Date: 2012-07-11 Impact factor: 3.240